期刊
JOURNAL OF THE AMERICAN HEART ASSOCIATION
卷 10, 期 21, 页码 -出版社
WILEY
DOI: 10.1161/JAHA.121.022274
关键词
atrial fibrillation; left atrial appendage; left atrial appendage occlusion; stroke
The majority of embolic strokes in patients with nonvalvular atrial fibrillation are caused by thrombi in the left atrial appendage. It is projected that strokes related to atrial fibrillation will increase unless effective mitigation strategies are implemented. Systemic anticoagulation is effective in reducing stroke risk, but bleeding complications and nonadherence can be barriers. Surgical and percutaneous left atrial appendage occlusion devices are nonpharmacologic strategies to mitigate drug therapy challenges.
The majority of embolic strokes in patients with nonvalvular atrial fibrillation are caused by thrombi in the left atrial appendage. It is projected that strokes related to atrial fibrillation will markedly increase in the future unless effective mitigation strategies are implemented. Systemic anticoagulation has been known to be highly effective in reducing stroke risk in patients with atrial fibrillation. However, bleeding complications and nonadherence are barriers to effective anticoagulation therapy. Surgical and percutaneous left atrial appendage occlusion devices are nonpharmacologic strategies to mitigate the challenges of drug therapy. We present a contemporary review of left atrial appendage occlusion for stroke prevention in nonvalvular atrial fibrillation. A thorough review of the history of surgical and percutaneous left atrial appendage occlusion devices, recent trials, and US Food and Drug Administration milestones of current left atrial appendage occlusion devices are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据